Compound ID | 1375
Class: Polymyxin
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Membrane-active agent |
| Target Pathogen: | Active against Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae |
| Description: | A polymyxin E analogue |
| Institute where first reported: | Spero Therapeutics Inc. |
| Year first mentioned: | 2019 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citation: | https://aac.asm.org/content/63/10/e00935-19 |